Disease intelligence · mutation landscape
Mesothelioma mutation landscape
How often each gene is altered in mesothelioma, in each sequenced cohort, over the patients on whom it could have been called. Copy number is its own row. Nothing is pooled.
Answer block
In Mesothelioma (TCGA, PanCancer Atlas) (86 sequenced patients, exome or genome), the most frequently altered of the 47 genes shown are CDKN2A 44.83% (deep deletion), NF2 23.26%, BAP1 20.93%, TP53 16.28%, SETD2 9.3%. Each figure divides by the patients on whom that gene could be called.
Of the briefing's 12 curated targets, 6 are altered in under 2% of this cohort (MSLN, CD274, PDCD1, CTLA4, VEGFA, ALK): targets by expression, dependency or drug label, not by mutation. Frequency is not targetability, in either direction.
1 cohorts are shown and none are pooled; overlap between them has not been checked and there is no disease-wide percentage.
Evidence boundary: frequency here is a count in a named cohort. Whether an alteration is a driver, is actionable, or has a drug is the briefing's question and is not inferred from these numbers.
What is altered, by cohort
One row per alteration, not per gene: a gene that is amplified and rarely mutated (ERBB2, MYCN, EGFR) gets a row for each. Every cell divides by its own denominator — the patients in that cohort on whom that gene could be called. Copy-number rows are shown only where at least one cohort reaches 2%.
| Alteration | meso_tcga_pan_can_atlas_2018 86 pts · exome or genome |
|---|---|
| BAP1 SNV / small indel | 20.93%18/86 |
| BAP1 deep deletion | 11.49%10/87 |
| CDKN2A SNV / small indel | 0% |
| CDKN2A deep deletion | 44.83%39/87 |
| NF2 SNV / small indel | 23.26%20/86 |
| NF2 deep deletion | 8.05%7/87 |
| TP53 SNV / small indel | 16.28%14/86 |
| SETD2 SNV / small indel | 9.3%8/86 |
| SETD2 deep deletion | 3.45%3/87 |
| LATS2 SNV / small indel | 9.3%8/86 |
| MSLN SNV / small indel | 0% |
| CD274 SNV / small indel | 1.16%1/86 |
| PDCD1 SNV / small indel | 0% |
| CTLA4 SNV / small indel | 0% |
| VEGFA SNV / small indel | 0% |
| ALK SNV / small indel | 1.16%1/86 |
| WWP2 SNV / small indel | 3.49%3/86 |
| VWF SNV / small indel | 3.49%3/86 |
| TDRD6 SNV / small indel | 3.49%3/86 |
| SRGAP3 SNV / small indel | 3.49%3/86 |
| SHROOM1 SNV / small indel | 3.49%3/86 |
| SETDB1 SNV / small indel | 3.49%3/86 |
| SDK1 SNV / small indel | 3.49%3/86 |
| PTCH1 SNV / small indel | 3.49%3/86 |
| PHRF1 SNV / small indel | 3.49%3/86 |
| OGDHL SNV / small indel | 3.49%3/86 |
| NLRP9 SNV / small indel | 3.49%3/86 |
| NLRP9 amplification | 2.3%2/87 |
| NLRP7 SNV / small indel | 3.49%3/86 |
| NEXMIF SNV / small indel | 3.49%3/86 |
| NDST2 SNV / small indel | 3.49%3/86 |
| NCOR1 SNV / small indel | 3.49%3/86 |
| MROH2B SNV / small indel | 3.49%3/86 |
| MGA SNV / small indel | 3.49%3/86 |
| MGA deep deletion | 4.6%4/87 |
| LRP4 SNV / small indel | 3.49%3/86 |
| FRY SNV / small indel | 3.49%3/86 |
| DNHD1 SNV / small indel | 3.49%3/86 |
| CRACD SNV / small indel | 3.49%3/86 |
| CNTNAP2 SNV / small indel | 3.49%3/86 |
| ALPK3 SNV / small indel | 3.49%3/86 |
| ALPK3 amplification | 4.6%4/87 |
| ZC3H4 SNV / small indel | 2.33%2/86 |
| ZBTB20 SNV / small indel | 2.33%2/86 |
| WDR89 SNV / small indel | 2.33%2/86 |
| VWA3B SNV / small indel | 2.33%2/86 |
| VPS13C SNV / small indel | 2.33%2/86 |
| VPS13C amplification | 2.3%2/87 |
| VEPH1 SNV / small indel | 2.33%2/86 |
| UTP20 SNV / small indel | 2.33%2/86 |
| USP9X SNV / small indel | 2.33%2/86 |
| USP9X deep deletion | 2.3%2/87 |
| TMEM132C SNV / small indel | 2.33%2/86 |
| TMEM132A SNV / small indel | 2.33%2/86 |
| TM9SF2 SNV / small indel | 2.33%2/86 |
| TLN2 SNV / small indel | 2.33%2/86 |
| TLN2 amplification | 2.3%2/87 |
observed — shade scales with frequency, full at 30% assayed, none found not on this cohort's panel cohort not readable
Key findings
CDKN2A is deleted in 39 of 87 patients in Mesothelioma (TCGA, PanCancer Atlas).
NF2 is mutated in 20 of 86 patients in Mesothelioma (TCGA, PanCancer Atlas).
BAP1 is mutated in 18 of 86 patients in Mesothelioma (TCGA, PanCancer Atlas).
Gene table — reference cohort
Headline values are from the reference cohort, meso_tcga_pan_can_atlas_2018; the matrix above keeps every cohort separate. "Curated" marks a gene the disease briefing lists as a target; the rest are here because they are among the most frequently mutated genes in the reference cohort. Recurrent changes are the reference cohort's commonest protein changes.
| Gene | Why listed | Largest alteration | Altered / tested | Frequency | Without hypermutated | Cohorts observed | Range across cohorts | Recurrent changes |
|---|---|---|---|---|---|---|---|---|
| BAP1 | curated target | SNV / small indel | 18 / 86 | 20.93% | — | 1 / 1 | 20.93–20.93% | I47Lfs*21 (n=1), E284* (n=1), Y418Wfs*9 (n=1), H169Tfs*18 (n=1), E182K (n=1) |
| CDKN2A | curated target | deep deletion | 39 / 87 | 44.83% mutation 0.0% | — | 0 / 1 | 0.0–0.0% | none recurrent |
| NF2 | curated target | SNV / small indel | 20 / 86 | 23.26% | — | 1 / 1 | 23.26–23.26% | R57* (n=1), X333_splice (n=1), W184* (n=1), Y144* (n=1), K449Rfs*45 (n=1) |
| TP53 | curated target | SNV / small indel | 14 / 86 | 16.28% | — | 1 / 1 | 16.28–16.28% | K132N (n=1), A276D (n=1), R196* (n=1), R273C (n=1), Q331* (n=1) |
| SETD2 | curated target | SNV / small indel | 8 / 86 | 9.3% | — | 1 / 1 | 9.3–9.3% | Q1998Rfs*3 (n=1), Q1287* (n=1), V1656F (n=1), T1753Nfs*36 (n=1), Q2142* (n=1) |
| LATS2 | curated target | SNV / small indel | 8 / 86 | 9.3% | — | 1 / 1 | 9.3–9.3% | N654Lfs*40 (n=1), R593Afs*63 (n=1), K697* (n=1), E541* (n=1), R717W (n=1) |
| MSLN | curated target | SNV / small indel | 0 / 86 | 0.0% | — | 0 / 1 | 0.0–0.0% | none recurrent |
| CD274 | curated target | SNV / small indel | 1 / 86 | 1.16% | — | 1 / 1 | 1.16–1.16% | L224F (n=1) |
| PDCD1 | curated target | SNV / small indel | 0 / 86 | 0.0% | — | 0 / 1 | 0.0–0.0% | none recurrent |
| CTLA4 | curated target | SNV / small indel | 0 / 86 | 0.0% | — | 0 / 1 | 0.0–0.0% | none recurrent |
| VEGFA | curated target | amplification | 1 / 87 | 1.15% mutation 0.0% | — | 0 / 1 | 0.0–0.0% | none recurrent |
| ALK | curated target | SNV / small indel | 1 / 86 | 1.16% | — | 1 / 1 | 1.16–1.16% | G955W (n=1) |
| WWP2 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | H385L (n=1), W336G (n=1), E551K (n=1) |
| VWF | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | K2621E (n=1), V43I (n=1), Q322Rfs*135 (n=1) |
| TDRD6 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | L1588F (n=1), A1990T (n=1), Q662R (n=1) |
| SRGAP3 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | S837F (n=1), R65H (n=1), D270N (n=1) |
| SHROOM1 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | A205V (n=1), D9N (n=1), W679* (n=1) |
| SETDB1 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | K674Sfs*73 (n=1), R1059Sfs*13 (n=1), R668* (n=1) |
| SDK1 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | H1926Y (n=1), P579_H583del (n=1), R444C (n=1) |
| PTCH1 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | E836G (n=1), X535_splice (n=1), Q576* (n=1), Q1020Sfs*29 (n=1) |
| PHRF1 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | L510Q (n=1), M1438R (n=1), A429D (n=1) |
| OGDHL | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | L926P (n=1), A464S (n=1), G668D (n=1) |
| NLRP9 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | R662Q (n=1), D414Y (n=1), R899H (n=1) |
| NLRP7 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | R829H (n=1), R289K (n=1), R302W (n=1) |
| NEXMIF | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | A801P (n=1), Q1263L (n=1), D381E (n=1) |
| NDST2 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | E202V (n=1), K22Q (n=1), L66F (n=1) |
| NCOR1 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | A1979V (n=1), K215* (n=1), S1970R (n=1) |
| MROH2B | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | M11I (n=1), D32N (n=1), A307D (n=1) |
| MGA | by frequency | deep deletion | 4 / 87 | 4.6% mutation 3.49% | — | 1 / 1 | 3.49–3.49% | E1337* (n=1), E2974K (n=1), R819H (n=1) |
| LRP4 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | W1568* (n=1), P1336S (n=1), R589C (n=1) |
| FRY | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | Q1543* (n=1), Y556* (n=1), A1727P (n=1) |
| DNHD1 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | E3607K (n=1), I361S (n=1), Q1716H (n=1) |
| CRACD | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | R246* (n=1), S663F (n=1), E391K (n=1) |
| CNTNAP2 | by frequency | SNV / small indel | 3 / 86 | 3.49% | — | 1 / 1 | 3.49–3.49% | P38T (n=1), R286Q (n=1), A135E (n=1) |
| ALPK3 | by frequency | amplification | 4 / 87 | 4.6% mutation 3.49% | — | 1 / 1 | 3.49–3.49% | I1503N (n=1), G1793V (n=1), R1516C (n=1) |
| ZC3H4 | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | V998Cfs*146 (n=1), D846V (n=1) |
| ZBTB20 | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | R613P (n=1), R109H (n=1) |
| WDR89 | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | L142W (n=2) |
| VWA3B | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | G276D (n=1), A80G (n=1) |
| VPS13C | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | K2304* (n=1), L3204F (n=1) |
| VEPH1 | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | Q118K (n=1), V58A (n=1) |
| UTP20 | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | G1919R (n=1), V784A (n=1) |
| USP9X | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | P2202R (n=1), S646Vfs*20 (n=1) |
| TMEM132C | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | R580W (n=1), R635* (n=1) |
| TMEM132A | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | R535L (n=1), E994K (n=1) |
| TM9SF2 | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | G556Yfs*47 (n=1), R31H (n=1) |
| TLN2 | by frequency | SNV / small indel | 2 / 86 | 2.33% | — | 1 / 1 | 2.33–2.33% | N1625S (n=1), G1094E (n=1) |
Cohorts
Listed in the disease profile, not searched: a name search returns the same patients under several accessions. Patients are unique patient ids in the study's sequenced sample list. Hypermutated: more than ten times the cohort's median non-silent mutations per sample, and at least 100.
| Cohort | Accession | Patients | Samples sequenced / in study | Assay | Panels (samples) | Build | Profiles read | Hypermutated patients | Median mutations / sample |
|---|---|---|---|---|---|---|---|---|---|
| Mesothelioma (TCGA, PanCancer Atlas) reference | meso_tcga_pan_can_atlas_2018 | 86 observed | 86 / 87 | exome or genome | WES (86) | hg19 | SNV, small indel, amplification, deep deletion, structural variant (profile present, not read) | 0 | 26.0 |
Copy-number events
Discrete calls from each study's copy-number profile: 2 is high-level amplification, −2 deep deletion. Gains and shallow losses are not counted. Denominators are the cohort's copy-number sample list, which differs from its sequenced list. Rows at 2% or more.
| Gene | Event | Observed patients | Tested patients | Frequency | Cohort | Profile |
|---|---|---|---|---|---|---|
| CDKN2A | deep deletion | 39 | 87 | 44.83% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
| BAP1 | deep deletion | 10 | 87 | 11.49% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
| NF2 | deep deletion | 7 | 87 | 8.05% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
| MGA | deep deletion | 4 | 87 | 4.6% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
| ALPK3 | amplification | 4 | 87 | 4.6% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
| SETD2 | deep deletion | 3 | 87 | 3.45% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
| NLRP9 | amplification | 2 | 87 | 2.3% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
| VPS13C | amplification | 2 | 87 | 2.3% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
| USP9X | deep deletion | 2 | 87 | 2.3% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
| TLN2 | amplification | 2 | 87 | 2.3% | meso_tcga_pan_can_atlas_2018 | meso_tcga_pan_can_atlas_2018_gistic |
Cohort-aware frequencies
Each row is calculated from unique patients in that study's sequenced sample list. The range is descriptive; no pooled estimate is shown because cross-study overlap and assay comparability have not been checked.
| Gene | Range | Per cohort (altered / tested) |
|---|---|---|
| BAP1 | 20.93–20.93% | meso_tcga_pan_can_atlas_2018: 18/86 (20.93%) |
| CDKN2A | 0.0–0.0% | meso_tcga_pan_can_atlas_2018: 0/86 (0.0%) |
| NF2 | 23.26–23.26% | meso_tcga_pan_can_atlas_2018: 20/86 (23.26%) |
| TP53 | 16.28–16.28% | meso_tcga_pan_can_atlas_2018: 14/86 (16.28%) |
| SETD2 | 9.3–9.3% | meso_tcga_pan_can_atlas_2018: 8/86 (9.3%) |
| LATS2 | 9.3–9.3% | meso_tcga_pan_can_atlas_2018: 8/86 (9.3%) |
| MSLN | 0.0–0.0% | meso_tcga_pan_can_atlas_2018: 0/86 (0.0%) |
| CD274 | 1.16–1.16% | meso_tcga_pan_can_atlas_2018: 1/86 (1.16%) |
| PDCD1 | 0.0–0.0% | meso_tcga_pan_can_atlas_2018: 0/86 (0.0%) |
| CTLA4 | 0.0–0.0% | meso_tcga_pan_can_atlas_2018: 0/86 (0.0%) |
| VEGFA | 0.0–0.0% | meso_tcga_pan_can_atlas_2018: 0/86 (0.0%) |
| ALK | 1.16–1.16% | meso_tcga_pan_can_atlas_2018: 1/86 (1.16%) |
| WWP2 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| VWF | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| TDRD6 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| SRGAP3 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| SHROOM1 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| SETDB1 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| SDK1 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| PTCH1 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| PHRF1 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| OGDHL | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| NLRP9 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| NLRP7 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| NEXMIF | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| NDST2 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| NCOR1 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| MROH2B | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| MGA | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| LRP4 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| FRY | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| DNHD1 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| CRACD | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| CNTNAP2 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| ALPK3 | 3.49–3.49% | meso_tcga_pan_can_atlas_2018: 3/86 (3.49%) |
| ZC3H4 | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| ZBTB20 | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| WDR89 | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| VWA3B | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| VPS13C | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| VEPH1 | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| UTP20 | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| USP9X | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| TMEM132C | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| TMEM132A | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| TM9SF2 | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
| TLN2 | 2.33–2.33% | meso_tcga_pan_can_atlas_2018: 2/86 (2.33%) |
What this page does not do
Structural variants
Read the structural-variant profiles the studies carry; fusions are the defining event in several of these diseases.
Context
Stage, subtype, age and treatment line are not attached to any count; the cohorts differ on all four.
Interpretation
Activating versus inactivating, actionable versus not, and evidence level are not inferred here; the briefing's target table carries the drug and trial facts.
Limitations
- A cBioPortal public-API snapshot retrieved 2026-09-18; the page does not refresh source data at request time.
- Counts are patients with at least one non-silent call in the study's sequenced sample list; silent, intronic and UTR calls are excluded.
- For targeted-panel cohorts each gene divides by the patients whose panel carried it; a gene absent from the panel is shown as not assayed, not as zero.
- Copy-number rows use discrete calls (2 = high-level amplification, −2 = deep deletion) against the cohort's copy-number sample list, which is a different roster from the sequenced one.
- Cohorts are not pooled. Cross-study patient overlap has not been checked and no disease-wide frequency is reported.
- Structural variants and fusions are not read in this snapshot even where the study carries a profile; germline variants, mutational signatures, TMB and MSI are not reported.
- The gene set is the briefing's curated targets plus the reference cohort's most frequently mutated genes; it is not genome-wide.
How a machine should read this page
- Denominators: every frequency divides by the patients in one named cohort on whom the gene could be called; there is no disease-wide figure.
- Missing values:
not_assayed(the panel did not carry the gene),not_observed(assayed, none found) andnot_evaluable(the cohort could not be read) are three different facts and are never converted to zero. - Counting: patients, not samples; several samples from one patient count once. Non-silent calls only.
- Copy number: a separate assay with a separate roster; discrete calls at ±2 only.
- Hypermutation: flagged per cohort; the headline keeps all patients and the frequency without them is reported beside it.
- Provenance: every value carries the study id, the retrieval date and the processing version; the source is the cBioPortal public API.
Machine endpoints: full landscape · genes · cohorts · the disease's own facts: /disease/mesothelioma.json.
Built by the BioTransfer briefings pipeline from the cBioPortal public API. The neuroblastoma page was assembled by hand and set the rules this page follows; how these are built.